معرفی
Bradley Doak is a Senior Lecturer in Medicinal Chemistry at Monash University, affiliated with the Faculty of Pharmacy and Pharmaceutical Sciences. He leads research in fragment-based drug design, focusing on antibacterial targets and protein inhibitors. His work contributes to sustainable development goals related to health and innovation.
Research Interests: Doak specializes in fragment-based approaches for drug discovery, particularly targeting bacterial enzymes like DsbA. His lab employs NMR spectroscopy, mass spectrometry, and X-ray crystallography to study ligand binding and design covalent modifiers. He also explores drug discovery principles beyond the Rule of 5 to expand bioavailable drug candidates.
Recent Article Trends: His publications (2020–2025) emphasize antibacterial agent development, protein-ligand interactions, and methodological advances in fragment screening. Key areas include novel DsbA inhibitors and structural studies of fatty acid-binding proteins.
Equipment Management: He co-manages the Monash Fragment Platform, a facility supporting drug discovery through advanced screening technologies.
